(Total Views: 480)
Posted On: 08/12/2020 11:11:10 AM
Post# of 153923
@misiu143
You are absolutely correct. The M/M cohort will probably not express meaningful viral load, or any associated delta.
However, my original point was that viral load was also likely not going to be included in the S/C analysis, as it does not appear in that protocol either.
With Dr.BP explaining last night that the FDA does NOT look at outside publications when making assessments for approval, I was only expressing regret that the soon-to-be-released peer-reviewed paper would not be seen by the FDA, and that we have effectively lost our ability to tell this important part of the story.
Antivirals like remedesivir do not lower COVID viral load -- while leronlimab, an immuno-modulatoer -- does. This is an incredibly important part of our story, that both the FDA and media need to hear and understand. But the opportunity seems to have slid through our fingers.
You are absolutely correct. The M/M cohort will probably not express meaningful viral load, or any associated delta.
However, my original point was that viral load was also likely not going to be included in the S/C analysis, as it does not appear in that protocol either.
With Dr.BP explaining last night that the FDA does NOT look at outside publications when making assessments for approval, I was only expressing regret that the soon-to-be-released peer-reviewed paper would not be seen by the FDA, and that we have effectively lost our ability to tell this important part of the story.
Antivirals like remedesivir do not lower COVID viral load -- while leronlimab, an immuno-modulatoer -- does. This is an incredibly important part of our story, that both the FDA and media need to hear and understand. But the opportunity seems to have slid through our fingers.
(3)
(0)
